Yoneyama Seigo, Fukui Ayumi, Sakurada Yoichi, Terao Nobuhiro, Kusada Natsuki, Kikushima Wataru, Kotoda Yumi, Mabuchi Fumihiko, Sotozono Chie, Kashiwagi Kenji
Department of Ophthalmology, University of Yamanashi, Yamanashi, JPN.
Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, JPN.
Cureus. 2024 Apr 20;16(4):e58631. doi: 10.7759/cureus.58631. eCollection 2024 Apr.
To compare the genetic and clinical characteristics of central serous chorioretinopathy (CSC) in patients with and without steroid use.
A total of 407 consecutive patients with CSC were included. Demographic data and clinical factors, including subfoveal choroidal thickness, bilateral involvement, descending tracts, pachydrusen, fibrin, and dome-shaped pigment epithelial detachment, were obtained. Variants of complement factor H (CFH)I62V (rs800292) and rs1329428 were genotyped in all cases using TaqMan technology.
Of the total patients, 48 (11.8%) were steroid users. The majority of males were non-steroid users (82.5%) than steroid users (58.3%) (p = 9.8 × 10). Demographic data and the prevalence of clinical factors were comparable between the two groups (all p-values > 0.10). Risk allele frequencies of CFH rs800292 and rs1329428 were also comparable between the two groups (p = 0.76, rs800292: steroid users = 52.1% vs. non-steroid users = 50.4%; p = 0.62, rs1329428: steroid users = 47.9% vs. non-steroid users = 45.3%).
Except for the male/female ratio, there were no significant differences in the clinical presentation or genetic characteristics, including variants of the CFH gene, between the two groups.
比较使用和未使用类固醇的中心性浆液性脉络膜视网膜病变（CSC）患者的基因和临床特征。
共纳入407例连续性CSC患者。获取人口统计学数据和临床因素，包括黄斑中心凹下脉络膜厚度、双侧受累情况、下降支、厚壁小疣、纤维蛋白和穹窿状色素上皮脱离。所有病例均采用TaqMan技术对补体因子H（CFH）I62V（rs800292）和rs1329428的变体进行基因分型。
在所有患者中，48例（11.8%）使用类固醇。男性中大多数是非类固醇使用者（82.5%），而非类固醇使用者（58.3%）（p = 9.8 × 10）。两组之间的人口统计学数据和临床因素患病率具有可比性（所有p值>0.10）。两组之间CFH rs800292和rs1329428的风险等位基因频率也具有可比性（p = 0.76，rs800292：类固醇使用者=52.1%，非类固醇使用者=50.4%；p = 0.62，rs1329428：类固醇使用者=47.9%，非类固醇使用者=45.3%）。
除男女比例外，两组在临床表现或基因特征（包括CFH基因变体）方面无显著差异。
